Small conjugate-based theranostic agents: an encouraging approach for cancer therapy
- Authors
- Kumar, Rajesh; Shin, Weon Sup; Sunwoo, Kyoung; Kim, Won Young; Koo, Seyoung; Bhuniya, Sankarprasad; Kim, Jong Seung
- Issue Date
- 2015
- Publisher
- ROYAL SOC CHEMISTRY
- Citation
- CHEMICAL SOCIETY REVIEWS, v.44, no.19, pp.6670 - 6683
- Indexed
- SCIE
SCOPUS
- Journal Title
- CHEMICAL SOCIETY REVIEWS
- Volume
- 44
- Number
- 19
- Start Page
- 6670
- End Page
- 6683
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/96188
- DOI
- 10.1039/c5cs00224a
- ISSN
- 0306-0012
- Abstract
- The advances in genomics, proteomics, and bioinformatics have directed the development of new anticancer agents to reduce drug abuse and increase safe and specific drug treatment. Theranostics, combining therapy and diagnosis, is an appealing approach for chemotherapy in medicine which exhibits improved biodistribution, selective cancer targeting ability, reduced toxicity, masked drug efficacy, and minimum side effects. The role of diagnosis tools in theranostics is to collect the information of the diseased state before and after specific treatment. Magnetic particle-, mesoporous silica-, various carbon allotrope-, and polymer nanoparticle-based theranostic systems are well accepted and clinically significant. Currently, small conjugate-based systems have received much attention for cancer treatment and diagnosis. The structural architecture of these systems is relatively simple, compact, biocompatible, and unidirectional. In this tutorial review, we summarize the latest developments on small conjugate based theranostic agents for tumor treatment and diagnosis using fluorescence and magnetic resonance imaging (MRI).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Science > Department of Chemistry > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.